Molecular Diagnostic Market Research Report 2033

Molecular Diagnostic Market Research Report 2033

Segments - by Product Type (Instruments, Reagents & Kits, Software & Services), by Technology (PCR, In Situ Hybridization, Isothermal Nucleic Acid Amplification, DNA Sequencing & NGS, Microarrays, Others), by Application (Infectious Diseases, Oncology, Genetic Testing, Blood Screening, Others), by End-User (Hospitals, Diagnostic Laboratories, Academic & Research Institutes, Others)

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vaibhav
Fact-checked by : V. Chandola
https://growthmarketreports.com/Shruti
Editor : Shruti Bhat

Upcoming | Report ID :HC-2011 | 4.7 Rating | 18 Reviews | 292 Pages | Format : Docx PDF

Report Description


Molecular Diagnostics Market Outlook

According to our latest research, the global molecular diagnostics market size reached USD 16.2 billion in 2024, driven by increasing demand for rapid and accurate disease detection technologies. The market is expected to grow at a robust CAGR of 7.8% from 2025 to 2033, reaching a projected value of USD 32.3 billion by 2033. This impressive growth trajectory is primarily attributed to the rising prevalence of infectious diseases, advancements in molecular testing technologies, and the expanding application of molecular diagnostics in personalized medicine.

One of the most significant growth factors fueling the molecular diagnostics market is the escalating incidence of infectious diseases globally. The ongoing threat of emerging pathogens, antimicrobial resistance, and the lingering impact of pandemics like COVID-19 have heightened the need for rapid, sensitive, and specific diagnostic tools. Molecular diagnostics, with its ability to detect pathogens at the genetic level, has become the gold standard for timely and accurate disease identification. Governments and healthcare organizations are increasingly investing in molecular testing infrastructure to strengthen disease surveillance and control, further propelling market growth.

Another key driver is the technological evolution within the molecular diagnostics landscape. Innovations such as real-time PCR, next-generation sequencing (NGS), and isothermal nucleic acid amplification have revolutionized the speed, accuracy, and scalability of molecular testing. These advancements have not only improved clinical outcomes but have also enabled the expansion of molecular diagnostics into non-traditional settings, including point-of-care and home-based testing. The integration of automation, digital platforms, and artificial intelligence into molecular diagnostics workflows is enhancing throughput, reducing human error, and making complex analyses more accessible to a broader range of healthcare providers.

The growing emphasis on personalized medicine and precision oncology is also significantly shaping the molecular diagnostics market. As healthcare shifts towards individualized treatment regimens, molecular diagnostics play a pivotal role in identifying genetic mutations, guiding targeted therapies, and monitoring disease progression. The ability to provide actionable insights at the molecular level is driving adoption in oncology, genetic testing, and pharmacogenomics. Furthermore, the declining costs of sequencing technologies and increasing awareness among clinicians about the benefits of molecular diagnostics are expected to sustain market momentum in the coming years.

From a regional perspective, North America continues to dominate the molecular diagnostics market, owing to its advanced healthcare infrastructure, high adoption of innovative technologies, and substantial investments in research and development. However, the Asia Pacific region is emerging as a rapidly growing market, fueled by improving healthcare access, rising disease burden, and supportive government initiatives. Europe also holds a significant share, with a strong focus on early disease detection and robust regulatory frameworks. Meanwhile, Latin America and the Middle East & Africa are witnessing steady growth, albeit from a smaller base, as healthcare modernization efforts accelerate in these regions.

Global Molecular Diagnostic Industry Outlook

Product Type Analysis

The molecular diagnostics market by product type is primarily segmented into instruments, reagents & kits, and software & services. Among these, reagents & kits represent the largest revenue-generating segment, accounting for a substantial portion of the market share in 2024. This dominance is largely due to the recurring nature of reagent and kit consumption in diagnostic workflows, as well as the increasing adoption of multiplex assays and ready-to-use kits. The need for continuous replenishment of reagents and the expansion of molecular testing menus in clinical laboratories are further driving the growth of this segment.

Instruments, which include PCR machines, sequencers, microarray platforms, and automated sample processors, are also experiencing robust demand. The ongoing trend towards laboratory automation and high-throughput testing is pushing manufacturers to develop next-generation instruments with enhanced sensitivity, faster turnaround times, and user-friendly interfaces. Hospitals and large diagnostic centers are particularly investing in advanced molecular diagnostic instruments to improve efficiency and meet the growing volume of tests, especially during public health emergencies.

The software & services segment is gaining momentum as digital transformation sweeps across the healthcare industry. Analytical software solutions are essential for managing the complex data generated by molecular diagnostic tests, particularly in next-generation sequencing and bioinformatics. Cloud-based platforms, data analytics, and artificial intelligence-driven interpretation tools are becoming integral to laboratory operations, enabling clinicians to derive actionable insights from vast datasets. Service offerings, such as instrument maintenance, training, and consulting, are also expanding as laboratories seek to optimize workflow and ensure regulatory compliance.

Overall, the interplay between these product segments is shaping the competitive dynamics of the molecular diagnostics market. Companies are increasingly offering integrated solutions that combine instruments, reagents, and software to streamline laboratory processes and deliver comprehensive value to end-users. The continual innovation in product design, coupled with strategic partnerships between diagnostics companies and healthcare providers, is expected to further enhance the adoption and effectiveness of molecular diagnostic technologies.

Report Scope

Attributes Details
Report Title Molecular Diagnostic Market Research Report 2033
By Product Type Instruments, Reagents & Kits, Software & Services
By Technology PCR, In Situ Hybridization, Isothermal Nucleic Acid Amplification, DNA Sequencing & NGS, Microarrays, Others
By Application Infectious Diseases, Oncology, Genetic Testing, Blood Screening, Others
By End-User Hospitals, Diagnostic Laboratories, Academic & Research Institutes, Others
Regions Covered North America, Europe, APAC, Latin America, MEA
Base Year 2024
Historic Data 2018-2023
Forecast Period 2025-2033
Number of Pages 292
Number of Tables & Figures 317
Customization Available Yes, the report can be customized as per your need.

Technology Analysis

The molecular diagnostics market is characterized by a diverse array of technologies, with polymerase chain reaction (PCR) remaining the cornerstone of molecular testing. PCR-based assays dominate due to their high sensitivity, specificity, and versatility in detecting a wide range of pathogens and genetic markers. The advent of real-time PCR and digital PCR has further improved quantification accuracy and enabled multiplexing capabilities, making PCR indispensable in clinical diagnostics, infectious disease screening, and oncology applications.

Next-generation sequencing (NGS) and DNA sequencing technologies are rapidly gaining traction, especially in the fields of oncology, genetic testing, and rare disease diagnosis. NGS allows for high-throughput, comprehensive analysis of genetic variations, enabling personalized treatment decisions and the identification of novel biomarkers. The decreasing cost of sequencing and the development of user-friendly platforms are making NGS more accessible to routine clinical laboratories, contributing to its accelerating adoption.

Isothermal nucleic acid amplification techniques, such as loop-mediated isothermal amplification (LAMP), are emerging as valuable alternatives to traditional PCR. These methods offer rapid amplification without the need for sophisticated thermal cyclers, making them ideal for point-of-care and resource-limited settings. The simplicity, speed, and cost-effectiveness of isothermal amplification are driving their integration into decentralized diagnostic workflows, particularly for infectious disease detection.

Microarrays and in situ hybridization technologies continue to play important roles in molecular diagnostics, particularly in research and specialized clinical applications. Microarrays enable the simultaneous analysis of thousands of genetic targets, facilitating large-scale studies of gene expression and genetic variation. In situ hybridization, including fluorescence in situ hybridization (FISH), is widely used in cytogenetics and cancer diagnostics for visualizing specific DNA or RNA sequences within cells. The ongoing refinement of these technologies, coupled with their integration into multi-modal diagnostic platforms, is expanding their utility in both clinical and research settings.

Application Analysis

Infectious diseases remain the largest application segment for molecular diagnostics, accounting for a significant share of market revenues in 2024. The ability of molecular tests to rapidly and accurately identify pathogens, including viruses, bacteria, and fungi, is critical in managing outbreaks, guiding treatment decisions, and monitoring antimicrobial resistance. The COVID-19 pandemic has further underscored the importance of molecular diagnostics in public health responses, leading to sustained investments in infectious disease testing infrastructure.

Oncology represents a fast-growing application area, as molecular diagnostics are increasingly used for cancer screening, diagnosis, prognosis, and therapy selection. The identification of genetic mutations, gene fusions, and other molecular alterations is central to the development of targeted therapies and immuno-oncology approaches. Liquid biopsy and companion diagnostics are gaining prominence within oncology, enabling minimally invasive cancer detection and real-time monitoring of treatment response.

Genetic testing is another critical application segment, encompassing carrier screening, prenatal diagnostics, newborn screening, and pharmacogenomics. Advances in molecular technologies have made it possible to detect a wide array of inherited disorders, chromosomal abnormalities, and single-gene mutations with unprecedented accuracy. The growing awareness of genetic risks and the increasing demand for personalized healthcare are fueling the expansion of molecular diagnostics in genetic testing.

Blood screening and other applications, such as transplant diagnostics and microbiome analysis, also contribute to the overall growth of the molecular diagnostics market. Blood screening, in particular, is essential for ensuring the safety of blood supplies by detecting infectious agents and genetic disorders in donors. The versatility and expanding utility of molecular diagnostics across diverse clinical scenarios underscore their central role in modern healthcare.

End-User Analysis

Hospitals are the primary end-users of molecular diagnostics, accounting for the largest share of market demand in 2024. The integration of molecular testing into hospital laboratories enables timely diagnosis, effective patient management, and improved clinical outcomes. Hospitals are increasingly adopting advanced molecular diagnostic platforms to address the growing burden of infectious diseases, cancer, and genetic disorders. The trend towards centralized laboratory services and the need for high-throughput testing are further driving hospital investments in molecular diagnostics.

Diagnostic laboratories, both independent and hospital-affiliated, represent another major end-user segment. These laboratories offer specialized molecular testing services to a wide range of healthcare providers, including clinics, physician offices, and public health agencies. The scalability, expertise, and ability to handle large test volumes make diagnostic laboratories key players in the molecular diagnostics ecosystem. The rise of reference laboratories and the outsourcing of complex molecular tests are contributing to the growth of this segment.

Academic and research institutes play a crucial role in advancing molecular diagnostics through basic and translational research. These institutions are at the forefront of developing novel assays, validating new biomarkers, and exploring the clinical utility of emerging technologies. Collaborative efforts between academia, industry, and healthcare providers are accelerating the translation of research findings into commercial diagnostic products and clinical practice.

Other end-users, such as blood banks, pharmaceutical companies, and contract research organizations, also utilize molecular diagnostics for specialized applications. Blood banks rely on molecular testing for donor screening and blood safety, while pharmaceutical companies use these technologies in drug development and clinical trials. The broadening scope of molecular diagnostics across diverse end-user segments highlights its versatility and growing importance in the global healthcare landscape.

Opportunities & Threats

The molecular diagnostics market presents significant opportunities for innovation and expansion, particularly in the areas of point-of-care testing and personalized medicine. The increasing demand for rapid, decentralized diagnostic solutions is driving the development of portable molecular testing platforms that can deliver accurate results outside traditional laboratory settings. These advancements are particularly beneficial in remote, resource-limited, and emergency environments, where timely diagnosis can have a profound impact on patient outcomes. Additionally, the growing adoption of precision medicine is creating opportunities for molecular diagnostics companies to develop companion diagnostics, pharmacogenomic tests, and multi-analyte panels tailored to individual patient profiles.

Another major opportunity lies in the integration of digital technologies and artificial intelligence into molecular diagnostics workflows. The vast amounts of data generated by next-generation sequencing and other high-throughput assays require advanced analytics, machine learning algorithms, and cloud-based platforms for effective interpretation and clinical decision support. Companies that can harness the power of digital health, interoperability, and data security will be well-positioned to capitalize on the evolving needs of healthcare providers and patients. Furthermore, the expansion of molecular diagnostics into emerging markets, supported by government initiatives and healthcare infrastructure development, offers significant growth potential for industry players.

Despite the promising outlook, the molecular diagnostics market faces certain restrainers, including stringent regulatory requirements and reimbursement challenges. The complex and evolving regulatory landscape, particularly in the United States and Europe, can delay product approvals and increase development costs for manufacturers. Additionally, the high cost of advanced molecular tests and limited reimbursement coverage in some regions may hinder adoption, especially in resource-constrained healthcare systems. Addressing these barriers through streamlined regulatory pathways, cost-effective product development, and evidence-based value demonstration will be critical for sustained market growth.

Regional Outlook

North America remains the largest regional market for molecular diagnostics, with a market size of approximately USD 6.8 billion in 2024. The region's leadership is underpinned by advanced healthcare infrastructure, high adoption rates of innovative diagnostic technologies, and significant investments in research and development. The presence of major industry players, favorable reimbursement policies, and a strong focus on early disease detection further bolster the market in the United States and Canada. North America's molecular diagnostics market is expected to maintain a healthy growth trajectory, supported by ongoing innovation and increasing demand for personalized medicine.

Europe holds the second-largest share in the global molecular diagnostics market, with a market size of around USD 4.2 billion in 2024. The region benefits from robust regulatory frameworks, comprehensive healthcare coverage, and a strong emphasis on preventive health measures. Countries such as Germany, the United Kingdom, and France are at the forefront of adopting molecular diagnostic technologies, particularly in oncology, infectious diseases, and genetic testing. The European market is projected to grow at a steady CAGR of 7.1% through 2033, driven by ongoing investments in healthcare modernization and research collaborations.

The Asia Pacific region is emerging as the fastest-growing market for molecular diagnostics, with a market size estimated at USD 3.1 billion in 2024 and an expected CAGR of 9.3% from 2025 to 2033. Rapid urbanization, rising healthcare awareness, and increasing government initiatives to improve diagnostic infrastructure are key factors driving market expansion across China, India, Japan, and Southeast Asian countries. The growing burden of infectious diseases and cancer, coupled with favorable regulatory reforms and public-private partnerships, is accelerating the adoption of molecular diagnostics in the region. Latin America and the Middle East & Africa collectively account for the remaining market share, with gradual growth expected as healthcare systems in these regions continue to evolve and modernize.

Molecular Diagnostic Market Statistics

Competitor Outlook

The molecular diagnostics market is characterized by intense competition and a dynamic landscape, with both established players and emerging companies striving to gain market share through innovation, strategic collaborations, and geographic expansion. Leading companies are focused on developing comprehensive product portfolios that span instruments, reagents, and software solutions, enabling end-to-end integration of molecular diagnostics workflows. The pursuit of technological differentiation, such as high-throughput platforms, multiplex assays, and digital health integration, is a key strategy for maintaining competitive advantage in this rapidly evolving sector.

Mergers and acquisitions are a prominent feature of the competitive landscape, as companies seek to expand their capabilities, access new markets, and accelerate product development. Strategic partnerships between diagnostics firms, pharmaceutical companies, academic institutions, and healthcare providers are facilitating the co-development of companion diagnostics, biomarker discovery, and translational research. The increasing emphasis on regulatory compliance, quality assurance, and evidence-based value demonstration is prompting companies to invest in robust clinical validation and post-market surveillance programs.

Innovation remains at the core of competitive differentiation, with companies investing heavily in research and development to introduce next-generation molecular diagnostic technologies. The integration of artificial intelligence, machine learning, and cloud-based analytics into diagnostic platforms is enabling more accurate, efficient, and scalable testing solutions. Companies are also focusing on expanding their presence in emerging markets through localized manufacturing, distribution partnerships, and tailored product offerings that address specific regional needs and regulatory requirements.

Major companies operating in the global molecular diagnostics market include Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Qiagen, Hologic, Bio-Rad Laboratories, Danaher Corporation (Cepheid), Siemens Healthineers, Illumina, and Agilent Technologies. Roche Diagnostics is recognized for its comprehensive portfolio of PCR and NGS-based assays, as well as its strong presence in both centralized and decentralized testing environments. Abbott Laboratories offers a wide range of molecular diagnostic solutions for infectious diseases, oncology, and genetic testing, with a focus on automation and connectivity.

Thermo Fisher Scientific is a leader in the development of high-throughput sequencing platforms, reagents, and bioinformatics software, serving both clinical and research applications. Qiagen is renowned for its sample preparation technologies and integrated molecular testing systems, with a strong focus on infectious disease diagnostics and oncology. Hologic specializes in molecular diagnostics for women’s health and infectious disease screening, leveraging advanced automation and multiplexing capabilities. Other notable players, such as Bio-Rad Laboratories, Danaher Corporation (Cepheid), Siemens Healthineers, Illumina, and Agilent Technologies, continue to drive innovation and market expansion through product launches, partnerships, and global distribution networks.

Key Players

  • Roche Diagnostics
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Qiagen N.V.
  • Bio-Rad Laboratories
  • Siemens Healthineers
  • Hologic Inc.
  • Danaher Corporation
  • Becton, Dickinson and Company (BD)
  • Agilent Technologies
  • Illumina Inc.
  • GenMark Diagnostics
  • Sysmex Corporation
  • bioMérieux SA
  • Cepheid (a Danaher company)
  • Luminex Corporation
  • PerkinElmer Inc.
  • Myriad Genetics
  • Grifols S.A.
  • QuidelOrtho Corporation
Molecular Diagnostic Market Overview

Segments

The Molecular Diagnostic market has been segmented on the basis of

Product Type

  • Instruments
  • Reagents & Kits
  • Software & Services

Technology

  • PCR
  • In Situ Hybridization
  • Isothermal Nucleic Acid Amplification
  • DNA Sequencing & NGS
  • Microarrays
  • Others

Application

  • Infectious Diseases
  • Oncology
  • Genetic Testing
  • Blood Screening
  • Others

End-User

  • Hospitals
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Others

Competitive Landscape

Key players competing in the North America molecular diagnostics market include Qiagen; Illumina, Inc.; F. Hoffmann-la Roche Ltd.; Danaher Corp.[Cepheid Inc.]; Agilent Technologies; EXACT Sciences Corp.; Abbott Laboratories; Becton, Dickinson & Company; Hologic Corp.; and Myriad Genetics, Inc.

Some of these players are using several market strategies such as collaborations, acquisitions, partnerships, merger, product launches, and capacity expansion to enhance their market shares and to generate revenue and raise their production line of the business in the coming years.

North America Molecular Diagnostic Market Key Players

Table Of Content

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Molecular Diagnostic Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Molecular Diagnostic Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Molecular Diagnostic Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the Molecular Diagnostic Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Molecular Diagnostic Market Size & Forecast, 2023-2032
      4.5.1 Molecular Diagnostic Market Size and Y-o-Y Growth
      4.5.2 Molecular Diagnostic Market Absolute $ Opportunity

Chapter 5 Global Molecular Diagnostic Market Analysis and Forecast By Product Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Product Type
      5.1.2 Basis Point Share (BPS) Analysis By Product Type
      5.1.3 Absolute $ Opportunity Assessment By Product Type
   5.2 Molecular Diagnostic Market Size Forecast By Product Type
      5.2.1 Instruments
      5.2.2 Reagents & Kits
      5.2.3 Software & Services
   5.3 Market Attractiveness Analysis By Product Type

Chapter 6 Global Molecular Diagnostic Market Analysis and Forecast By Technology
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Technology
      6.1.2 Basis Point Share (BPS) Analysis By Technology
      6.1.3 Absolute $ Opportunity Assessment By Technology
   6.2 Molecular Diagnostic Market Size Forecast By Technology
      6.2.1 PCR
      6.2.2 In Situ Hybridization
      6.2.3 Isothermal Nucleic Acid Amplification
      6.2.4 DNA Sequencing & NGS
      6.2.5 Microarrays
      6.2.6 Others
   6.3 Market Attractiveness Analysis By Technology

Chapter 7 Global Molecular Diagnostic Market Analysis and Forecast By Application
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities By Application
      7.1.2 Basis Point Share (BPS) Analysis By Application
      7.1.3 Absolute $ Opportunity Assessment By Application
   7.2 Molecular Diagnostic Market Size Forecast By Application
      7.2.1 Infectious Diseases
      7.2.2 Oncology
      7.2.3 Genetic Testing
      7.2.4 Blood Screening
      7.2.5 Others
   7.3 Market Attractiveness Analysis By Application

Chapter 8 Global Molecular Diagnostic Market Analysis and Forecast By End-User
   8.1 Introduction
      8.1.1 Key Market Trends & Growth Opportunities By End-User
      8.1.2 Basis Point Share (BPS) Analysis By End-User
      8.1.3 Absolute $ Opportunity Assessment By End-User
   8.2 Molecular Diagnostic Market Size Forecast By End-User
      8.2.1 Hospitals
      8.2.2 Diagnostic Laboratories
      8.2.3 Academic & Research Institutes
      8.2.4 Others
   8.3 Market Attractiveness Analysis By End-User

Chapter 9 Global Molecular Diagnostic Market Analysis and Forecast by Region
   9.1 Introduction
      9.1.1 Key Market Trends & Growth Opportunities By Region
      9.1.2 Basis Point Share (BPS) Analysis By Region
      9.1.3 Absolute $ Opportunity Assessment By Region
   9.2 Molecular Diagnostic Market Size Forecast By Region
      9.2.1 North America
      9.2.2 Europe
      9.2.3 Asia Pacific
      9.2.4 Latin America
      9.2.5 Middle East & Africa (MEA)
   9.3 Market Attractiveness Analysis By Region

Chapter 10 Coronavirus Disease (COVID-19) Impact 
   10.1 Introduction 
   10.2 Current & Future Impact Analysis 
   10.3 Economic Impact Analysis 
   10.4 Government Policies 
   10.5 Investment Scenario

Chapter 11 North America Molecular Diagnostic Analysis and Forecast
   11.1 Introduction
   11.2 North America Molecular Diagnostic Market Size Forecast by Country
      11.2.1 U.S.
      11.2.2 Canada
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 North America Molecular Diagnostic Market Size Forecast By Product Type
      11.6.1 Instruments
      11.6.2 Reagents & Kits
      11.6.3 Software & Services
   11.7 Basis Point Share (BPS) Analysis By Product Type 
   11.8 Absolute $ Opportunity Assessment By Product Type 
   11.9 Market Attractiveness Analysis By Product Type
   11.10 North America Molecular Diagnostic Market Size Forecast By Technology
      11.10.1 PCR
      11.10.2 In Situ Hybridization
      11.10.3 Isothermal Nucleic Acid Amplification
      11.10.4 DNA Sequencing & NGS
      11.10.5 Microarrays
      11.10.6 Others
   11.11 Basis Point Share (BPS) Analysis By Technology 
   11.12 Absolute $ Opportunity Assessment By Technology 
   11.13 Market Attractiveness Analysis By Technology
   11.14 North America Molecular Diagnostic Market Size Forecast By Application
      11.14.1 Infectious Diseases
      11.14.2 Oncology
      11.14.3 Genetic Testing
      11.14.4 Blood Screening
      11.14.5 Others
   11.15 Basis Point Share (BPS) Analysis By Application 
   11.16 Absolute $ Opportunity Assessment By Application 
   11.17 Market Attractiveness Analysis By Application
   11.18 North America Molecular Diagnostic Market Size Forecast By End-User
      11.18.1 Hospitals
      11.18.2 Diagnostic Laboratories
      11.18.3 Academic & Research Institutes
      11.18.4 Others
   11.19 Basis Point Share (BPS) Analysis By End-User 
   11.20 Absolute $ Opportunity Assessment By End-User 
   11.21 Market Attractiveness Analysis By End-User

Chapter 12 Europe Molecular Diagnostic Analysis and Forecast
   12.1 Introduction
   12.2 Europe Molecular Diagnostic Market Size Forecast by Country
      12.2.1 Germany
      12.2.2 France
      12.2.3 Italy
      12.2.4 U.K.
      12.2.5 Spain
      12.2.6 Russia
      12.2.7 Rest of Europe
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Europe Molecular Diagnostic Market Size Forecast By Product Type
      12.6.1 Instruments
      12.6.2 Reagents & Kits
      12.6.3 Software & Services
   12.7 Basis Point Share (BPS) Analysis By Product Type 
   12.8 Absolute $ Opportunity Assessment By Product Type 
   12.9 Market Attractiveness Analysis By Product Type
   12.10 Europe Molecular Diagnostic Market Size Forecast By Technology
      12.10.1 PCR
      12.10.2 In Situ Hybridization
      12.10.3 Isothermal Nucleic Acid Amplification
      12.10.4 DNA Sequencing & NGS
      12.10.5 Microarrays
      12.10.6 Others
   12.11 Basis Point Share (BPS) Analysis By Technology 
   12.12 Absolute $ Opportunity Assessment By Technology 
   12.13 Market Attractiveness Analysis By Technology
   12.14 Europe Molecular Diagnostic Market Size Forecast By Application
      12.14.1 Infectious Diseases
      12.14.2 Oncology
      12.14.3 Genetic Testing
      12.14.4 Blood Screening
      12.14.5 Others
   12.15 Basis Point Share (BPS) Analysis By Application 
   12.16 Absolute $ Opportunity Assessment By Application 
   12.17 Market Attractiveness Analysis By Application
   12.18 Europe Molecular Diagnostic Market Size Forecast By End-User
      12.18.1 Hospitals
      12.18.2 Diagnostic Laboratories
      12.18.3 Academic & Research Institutes
      12.18.4 Others
   12.19 Basis Point Share (BPS) Analysis By End-User 
   12.20 Absolute $ Opportunity Assessment By End-User 
   12.21 Market Attractiveness Analysis By End-User

Chapter 13 Asia Pacific Molecular Diagnostic Analysis and Forecast
   13.1 Introduction
   13.2 Asia Pacific Molecular Diagnostic Market Size Forecast by Country
      13.2.1 China
      13.2.2 Japan
      13.2.3 South Korea
      13.2.4 India
      13.2.5 Australia
      13.2.6 South East Asia (SEA)
      13.2.7 Rest of Asia Pacific (APAC)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Asia Pacific Molecular Diagnostic Market Size Forecast By Product Type
      13.6.1 Instruments
      13.6.2 Reagents & Kits
      13.6.3 Software & Services
   13.7 Basis Point Share (BPS) Analysis By Product Type 
   13.8 Absolute $ Opportunity Assessment By Product Type 
   13.9 Market Attractiveness Analysis By Product Type
   13.10 Asia Pacific Molecular Diagnostic Market Size Forecast By Technology
      13.10.1 PCR
      13.10.2 In Situ Hybridization
      13.10.3 Isothermal Nucleic Acid Amplification
      13.10.4 DNA Sequencing & NGS
      13.10.5 Microarrays
      13.10.6 Others
   13.11 Basis Point Share (BPS) Analysis By Technology 
   13.12 Absolute $ Opportunity Assessment By Technology 
   13.13 Market Attractiveness Analysis By Technology
   13.14 Asia Pacific Molecular Diagnostic Market Size Forecast By Application
      13.14.1 Infectious Diseases
      13.14.2 Oncology
      13.14.3 Genetic Testing
      13.14.4 Blood Screening
      13.14.5 Others
   13.15 Basis Point Share (BPS) Analysis By Application 
   13.16 Absolute $ Opportunity Assessment By Application 
   13.17 Market Attractiveness Analysis By Application
   13.18 Asia Pacific Molecular Diagnostic Market Size Forecast By End-User
      13.18.1 Hospitals
      13.18.2 Diagnostic Laboratories
      13.18.3 Academic & Research Institutes
      13.18.4 Others
   13.19 Basis Point Share (BPS) Analysis By End-User 
   13.20 Absolute $ Opportunity Assessment By End-User 
   13.21 Market Attractiveness Analysis By End-User

Chapter 14 Latin America Molecular Diagnostic Analysis and Forecast
   14.1 Introduction
   14.2 Latin America Molecular Diagnostic Market Size Forecast by Country
      14.2.1 Brazil
      14.2.2 Mexico
      14.2.3 Rest of Latin America (LATAM)
   14.3 Basis Point Share (BPS) Analysis by Country
   14.4 Absolute $ Opportunity Assessment by Country
   14.5 Market Attractiveness Analysis by Country
   14.6 Latin America Molecular Diagnostic Market Size Forecast By Product Type
      14.6.1 Instruments
      14.6.2 Reagents & Kits
      14.6.3 Software & Services
   14.7 Basis Point Share (BPS) Analysis By Product Type 
   14.8 Absolute $ Opportunity Assessment By Product Type 
   14.9 Market Attractiveness Analysis By Product Type
   14.10 Latin America Molecular Diagnostic Market Size Forecast By Technology
      14.10.1 PCR
      14.10.2 In Situ Hybridization
      14.10.3 Isothermal Nucleic Acid Amplification
      14.10.4 DNA Sequencing & NGS
      14.10.5 Microarrays
      14.10.6 Others
   14.11 Basis Point Share (BPS) Analysis By Technology 
   14.12 Absolute $ Opportunity Assessment By Technology 
   14.13 Market Attractiveness Analysis By Technology
   14.14 Latin America Molecular Diagnostic Market Size Forecast By Application
      14.14.1 Infectious Diseases
      14.14.2 Oncology
      14.14.3 Genetic Testing
      14.14.4 Blood Screening
      14.14.5 Others
   14.15 Basis Point Share (BPS) Analysis By Application 
   14.16 Absolute $ Opportunity Assessment By Application 
   14.17 Market Attractiveness Analysis By Application
   14.18 Latin America Molecular Diagnostic Market Size Forecast By End-User
      14.18.1 Hospitals
      14.18.2 Diagnostic Laboratories
      14.18.3 Academic & Research Institutes
      14.18.4 Others
   14.19 Basis Point Share (BPS) Analysis By End-User 
   14.20 Absolute $ Opportunity Assessment By End-User 
   14.21 Market Attractiveness Analysis By End-User

Chapter 15 Middle East & Africa (MEA) Molecular Diagnostic Analysis and Forecast
   15.1 Introduction
   15.2 Middle East & Africa (MEA) Molecular Diagnostic Market Size Forecast by Country
      15.2.1 Saudi Arabia
      15.2.2 South Africa
      15.2.3 UAE
      15.2.4 Rest of Middle East & Africa (MEA)
   15.3 Basis Point Share (BPS) Analysis by Country
   15.4 Absolute $ Opportunity Assessment by Country
   15.5 Market Attractiveness Analysis by Country
   15.6 Middle East & Africa (MEA) Molecular Diagnostic Market Size Forecast By Product Type
      15.6.1 Instruments
      15.6.2 Reagents & Kits
      15.6.3 Software & Services
   15.7 Basis Point Share (BPS) Analysis By Product Type 
   15.8 Absolute $ Opportunity Assessment By Product Type 
   15.9 Market Attractiveness Analysis By Product Type
   15.10 Middle East & Africa (MEA) Molecular Diagnostic Market Size Forecast By Technology
      15.10.1 PCR
      15.10.2 In Situ Hybridization
      15.10.3 Isothermal Nucleic Acid Amplification
      15.10.4 DNA Sequencing & NGS
      15.10.5 Microarrays
      15.10.6 Others
   15.11 Basis Point Share (BPS) Analysis By Technology 
   15.12 Absolute $ Opportunity Assessment By Technology 
   15.13 Market Attractiveness Analysis By Technology
   15.14 Middle East & Africa (MEA) Molecular Diagnostic Market Size Forecast By Application
      15.14.1 Infectious Diseases
      15.14.2 Oncology
      15.14.3 Genetic Testing
      15.14.4 Blood Screening
      15.14.5 Others
   15.15 Basis Point Share (BPS) Analysis By Application 
   15.16 Absolute $ Opportunity Assessment By Application 
   15.17 Market Attractiveness Analysis By Application
   15.18 Middle East & Africa (MEA) Molecular Diagnostic Market Size Forecast By End-User
      15.18.1 Hospitals
      15.18.2 Diagnostic Laboratories
      15.18.3 Academic & Research Institutes
      15.18.4 Others
   15.19 Basis Point Share (BPS) Analysis By End-User 
   15.20 Absolute $ Opportunity Assessment By End-User 
   15.21 Market Attractiveness Analysis By End-User

Chapter 16 Competition Landscape 
   16.1 Molecular Diagnostic Market: Competitive Dashboard
   16.2 Global Molecular Diagnostic Market: Market Share Analysis, 2023
   16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      16.3.1 Roche Diagnostics
Abbott Laboratories
Thermo Fisher Scientific
Qiagen N.V.
Bio-Rad Laboratories
Siemens Healthineers
Hologic Inc.
Danaher Corporation
Becton, Dickinson and Company (BD)
Agilent Technologies
Illumina Inc.
GenMark Diagnostics
Sysmex Corporation
bioMérieux SA
Cepheid (a Danaher company)
Luminex Corporation
PerkinElmer Inc.
Myriad Genetics
Grifols S.A.
QuidelOrtho Corporation

Methodology

Our Clients

The John Holland Group
Pfizer
Deloitte
General Electric
Honda Motor Co. Ltd.
Nestle SA
Dassault Aviation
sinopec